Nevena Ilieva | Oncology | Best Researcher Award

Dr. Nevena Ilieva | Oncology | Best Researcher AwardΒ 

Doctorate, at Clinical Pathology Department, Complex Oncology Center Plovdiv, Bul. Vasil Aprilov 15A, 4000 Plovdiv, Bulgaria.

Dr. Nevena Ilieva is a dedicated physician and researcher specializing in clinical pathology. With a medical degree from the Medical University of Plovdiv, she has been serving as a Resident Physician at the Department of Clinical Pathology, COC-Plovdiv, since 2019. Dr. Ilieva is also an Honorary Assistant at the Medical University of Plovdiv. Her research focuses on colorectal and breast cancers, particularly exploring neoadjuvant immunotherapy’s effects on tumor biology. She is deeply committed to advancing personalized diagnostics and therapies in oncology, making significant contributions through her work in molecular mechanisms and tumor response analysis.

Profile

Scopus

Google Scholar

ORCID

πŸŽ“ Education

Dr. Ilieva’s academic journey began at Plovdiv Language School, where she studied German from 2008 to 2013. She then pursued her medical education at the Medical University of Plovdiv, earning her MD in 2019. Her rigorous training equipped her with comprehensive knowledge and practical skills in clinical pathology, setting the foundation for her specialization in oncology research. Her academic excellence laid the groundwork for a career dedicated to medical advancement and innovation in cancer treatment.

πŸ₯ Work Experience

Dr. Ilieva began her professional journey in 2019 as a Resident Physician in Clinical Pathology at COC-Plovdiv. She deepened her expertise with an honorary assistantship at the Medical University of Plovdiv, starting in September 2021. Her dual roles involve diagnosing complex cases and guiding medical students. Through meticulous histological analysis and immunohistochemistry, she contributes significantly to advancing diagnostic precision. Her experience underscores a commitment to excellence and innovation in pathology, particularly in oncology-focused research and clinical practice.

πŸ”¬ Research Interests

Dr. Ilieva’s research centers on colorectal tumors and breast cancer, with a focus on neoadjuvant immunotherapy and tumor biology. She investigates the molecular mechanisms of tumor response to treatments, especially PD-L1 expression and the immune microenvironment’s dynamics. Proficient in histological and immunohistochemical techniques, she applies robust statistical analyses to clinicopathological data. Her work aims to refine personalized oncology approaches, enhancing diagnostic accuracy and therapeutic strategies. This dedication reflects her passion for bridging research and clinical practice for better patient outcomes.

πŸ† Awards and Recognitions

Dr. Ilieva has been recognized for her contributions to clinical pathology and oncology research. Her commitment to excellence in diagnostics and personalized therapy has earned her prestigious memberships in leading international organizations, reflecting her standing in the medical community. She actively participates in conferences and workshops, continually expanding her professional horizons. Her work in immunotherapy and cancer research highlights her as an emerging leader in the field, poised for further accolades and groundbreaking contributions.

πŸ“š Top Noted Publications

Dr. Ilieva has authored several impactful publications in oncology and clinical pathology:

  • “Title of Publication 1” (2022) – Published in Journal Name [Link] (Cited by 10 articles)
  • “Title of Publication 2” (2021) – Published in Journal Name [Link] (Cited by 8 articles)
  • “Title of Publication 3” (2020) – Published in Journal Name [Link] (Cited by 5 articles)

Conclusion

Dr. Nevena Ilieva demonstrates significant potential as a candidate for the Best Researcher Award. Her innovative focus on colorectal and breast cancer, combined with her technical skills and active participation in global pathology networks, positions her as a promising researcher in oncology. Strengthening her profile through publications, funding acquisition, and collaborative research projects would further solidify her candidacy and make her a strong contender for this award.

 

Hai Huang| Prostate cancer| Best Researcher Award

Prof. Hai Huang| Prostate cancer| Best Researcher Award

Professor Hai Huang is a distinguished academic and researcher at Sun Yat-sen Memorial Hospital, specializing in the study of drug resistance mechanisms in prostate cancer. His research primarily focuses on understanding how the tumor microenvironment affects resistance to androgen receptor-targeted therapies and chemotherapy, aiming to develop better treatment strategies and improve patient outcomes. With an impressive portfolio, Professor Huang has completed 30 research projects, published 97 journal articles in SCI and Scopus-indexed journals, authored 9 books, and holds 20 patents.

Profiles

Scopus

Orcid

 

πŸ“šAcademic and Professional Background:

We focus on the research field of drug resistance mechanisms in prostate cancer, aiming to explore the tumor microenvironment’s role in androgen receptor-targeted therapy and chemotherapy resistance. Our work seeks to improve therapeutic strategies and patient outcomes in prostate cancer treatment.

πŸ“ŠΒ Research and Innovations:

Completed/Ongoing Research Projects:Β  30 , Citation Index:Β  (Hai Huang[Author])Β  ANDΒ  (Sun Yat-sen Memorial Hospital [Affiliation]) ,Consultancy/Industry Projects:Β  Prostate Cancer , Books Published (ISBN): Β 9 ,Β Patents Published/Under Process: 20 , Journals Published (SCI, Scopus, etc.):Β  97

🀝 Collaborations:

Qin Jun:Β CAS Key Laboratory of Tissue Microenvironment and Tumor, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Nutrition and Health, Shanghai Jiao Tong University School of Medicine (SJTUSM) & Chinese Academy of Sciences ,Β Β Gao Dong:Β State Key Laboratory of Cell Biology, Shanghai Key Laboratory of Molecular Andrology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences

πŸ†Β Professional Memberships:Β 

American Urological Association, European Association of Urology

πŸ”¬Β Areas of Research:Β 

Prostate cancer treatment resistance

πŸ†Β Contributions :

Focusing on mechanistic research of prostate cancer progression, I have published over 60 SCI papers as the first or corresponding author, with a total impact factor of 507. I have presented at numerous international urological conferences, sharing insights and advancements in prostate cancer treatment.

✍️ Self-Declaration:

I authenticate that to the best of my knowledge, the information given in this form is correct and complete. If at any time I am found to have concealed any material information, my application shall be liable to be summarily terminated without notice. I have read the terms and conditions and other policies of the Awards and agree to them.

πŸ“š Publications :

  • 🧬 Single-cell deconvolution algorithms analysis unveils autocrine IL11-mediated resistance to docetaxel in prostate cancer via activation of the JAK1/STAT4 pathway
    • Authors: Cheng, B., Li, L., Luo, T., Lai, Y., Huang, H.
    • Journal: Journal of Experimental and Clinical Cancer Research, 2024, 43(1), 67

 

  • πŸ”„ Correction: The key cellular senescence related molecule RRM2 regulates prostate cancer progression and resistance to docetaxel treatment
    • Authors: Cheng, B., Li, L., Wu, Y., Du, T., Huang, H.
    • Journal: Cell and Bioscience, 2024, 14(1), 17

 

  • πŸ”¬ A protein-encoding CCDC7 circular RNA inhibits the progression of prostate cancer by up-regulating FLRT3
    • Authors: Wang, Q., Cheng, B., Singh, S., Li, H., Huang, H.
    • Journal: npj Precision Oncology, 2024, 8(1), 11.

 

  • πŸ’Š Redox responsive polymeric nanoparticles enhance the efficacy of cyclin dependent kinase 7 inhibitor for enhanced treatment of prostate cancer
    • Authors: Tao, Y., Dai, C., Xie, Z., Wu, J., Huang, H.
    • Journal: Chinese Chemical Letters, 2024, 35(8), 109170

 

  • 🧩 Cancer-associated fibroblasts promote enzalutamide resistance and PD-L1 expression in prostate cancer through CCL5-CCR5 paracrine axis
    • Authors: Xiong, Z., Yu, S.-L., Xie, Z.-X., Huang, H., Li, K.-W.
    • Journal: iScience, 2024, 27(5), 109674

 

  • πŸ§ͺ MT1G, an emerging ferroptosis-related gene: A novel prognostic biomarker and indicator of immunotherapy sensitivity in prostate cancer
    • Authors: Cheng, B., Lai, Y., Huang, H., Wang, Q., Huang, H.
    • Journal: Environmental Toxicology, 2024, 39(2), pp. 927–941